<SEC-DOCUMENT>0001178913-22-002488.txt : 20220628
<SEC-HEADER>0001178913-22-002488.hdr.sgml : 20220628
<ACCEPTANCE-DATETIME>20220628071431
ACCESSION NUMBER:		0001178913-22-002488
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220628
FILED AS OF DATE:		20220628
DATE AS OF CHANGE:		20220628

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioLineRx Ltd.
		CENTRAL INDEX KEY:			0001498403
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35223
		FILM NUMBER:		221046491

	BUSINESS ADDRESS:	
		STREET 1:		2 HAMA-AYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		STATE:			L3
		ZIP:			7177871
		BUSINESS PHONE:		972-2-548-9100

	MAIL ADDRESS:	
		STREET 1:		2 HAMA-AYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		STATE:			L3
		ZIP:			7177871

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioLineRX, Ltd.
		DATE OF NAME CHANGE:	20100805
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2228056.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">WASHINGTON, D.C. 20549</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">FORM 6-K</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16 OF</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">For the month of June 2022</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Commission file number: 001-35223</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">_______________________</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">BioLineRx Ltd.</div>
      <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">_______________________</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">2 HaMa&#8217;ayan Street<br>
        Modi&#8217;in 7177871, Israel</div>
      <div style="text-align: center; line-height: 1.25;">&#160;(Address of Principal Executive Offices)</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">_______________________</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: &#160; &#160; &#160;&#160;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Form 20-F &#9746;&#160; &#160; &#160; &#160; Form 40-F&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">On June 28, 2022, the registrant issued the press release which is filed as&#160;<a href="exhibit_1.htm">Exhibit 1</a>&#160;to this Report on Form 6-K.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The first two paragraphs of the press release attached to this Form 6-K are hereby incorporated by reference into all effective
        registration statements filed by the registrant under the Securities Act of 1933.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
        behalf by the undersigned, thereunto duly authorized.</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z6a318486265048db8f316a91988448f7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="vertical-align: top;" colspan="2">
              <div style="line-height: 1.25; font-weight: bold;">BioLineRx Ltd.</div>
              <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
            </td>
            <td style="width: 22%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25;">By:</div>
            </td>
            <td style="width: 24.73%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="line-height: 1.25;">/s/ Philip A. Serlin</div>
            </td>
            <td style="width: 22%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 24.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Philip A. Serlin</div>
            </td>
            <td style="width: 22%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 24.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Chief Executive Officer</div>
            </td>
            <td style="width: 22%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">Dated: June 28, 2022</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <br>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit_1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"> <u><font style="font-weight: bold;">Exhibit 1</font></u><br>
    </div>
    <div>
      <div id="DSPFPageHeader">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><img width="285" height="38" src="image0.jpg"></div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25; font-weight: bold;">For Immediate Release</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">BioLineRx Announces Collaboration Agreement with </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">GenFleet Therapeutics to Further Develop Motixafortide in </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Pancreatic Ductal Adenocarcinoma (PDAC)</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">- GenFleet to design and execute randomized Phase 2b triple combination trial</div>
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">of Motixafortide in first-line metastatic PDAC patients in China -</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">- BioLineRx to retain global rights to Motixafortide in all indications -</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">-Collaboration based on positive final results from Phase 2a COMBAT/KEYNOTE-202 </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">study of Motixafortide in combination with anti-PD-1 and chemotherapy</div>
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">as second-line metastatic PDAC therapy -</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Tel Aviv, Israel, June 28, 2022 &#8211; BioLineRx Ltd. (NASDAQ/TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that the Company has entered into a
        collaboration agreement with GenFleet Therapeutics, an immuno-oncology focused biopharmaceutical company based in China, to advance Motixafortide through a randomized Phase 2b clinical trial in pancreatic ductal adenocarcinoma, or PDAC.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Under the terms of the agreement, GenFleet will fully fund, design and execute a randomized Phase 2b clinical trial that will enroll approximately 200 first-line metastatic PDAC patients in China.
        This randomized controlled study will aim to evaluate the superiority of Motixafortide in combination with an anti-PD-1 and chemotherapy compared to chemotherapy alone, the current standard of care. As part of the collaboration, BioLineRx will
        supply Motixafortide, while GenFleet will supply the other study drugs for the trial. Trial oversight will be administered by a Joint Development Committee. GenFleet&#160;will be eligible to receive low-to-mid-single digit tiered percentage royalties on
        future Motixafortide sales, if approved.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;This collaboration is based on the highly encouraging results from our Phase 2a <u>COMBAT/KEYNOTE-202 study</u> of Motixafortide in combination with an anti-PD-1 and chemotherapy, which provide
        strong support for continued development in this very challenging disease,&#8221; stated Philip Serlin, Chief Executive Officer of BioLineRx. &#8220;With its broad solid tumor oncology pipeline and highly experienced development team, we believe we have found
        an outstanding partner in GenFleet to execute a rigorously designed randomized Phase 2b trial.&#8221;</div>
      <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;At the same time, we remain on track to submit our New Drug Application (NDA) for Motixafortide in stem cell mobilization in the U.S. in the next few months, and we are continuing our pre-launch
        activities in anticipation of potential FDA approval in 2023.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;Together, these programs demonstrate the potential versatility of Motixafortide and its promise of new combination therapies targeting both hematological and solid tumor cancers,&#8221; Mr. Serlin
        concluded.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;The results of the COMBAT/KEYNOTE-202 Phase 2a study demonstrate the benefit of&#160;combining the CXCR4 inhibitor Motixafortide with an anti-PD-1 and chemotherapy in a second-line setting,&#8221; said Qiang
        Lu, Chairman of GenFleet. &#8220;We believe that this combination could be beneficial to patients in a first-line setting as well, and we hope to confirm this in a randomized trial. We are thrilled to be partners with BioLineRx in the development of this
        late-stage clinical asset, and look forward to initiating this important trial as quickly as possible.&#8221;</div>
      <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">In parallel, BioLineRx is continuing its <u>collaboration with Colombia University</u> in an on-going Phase 2 investigator-initiated study (NCT04543071) to evaluate&#160; Motixafortide in combination
        with the anti-PD-1 LIBTAYO<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (cemiplimab) and standard-of-care chemotherapy (gemcitabine and nab-paclitaxel) in first-line PDAC patients.</div>
      <div style="text-align: justify; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; line-height: 1.25;">
        <div style="line-height: 1.25;">MSQ Ventures served as advisor to BioLineRx on this transaction.</div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About Pancreatic Cancer</div>
      <div style="text-align: justify; line-height: 1.25;">
        <div style="line-height: 1.25;">Pancreatic cancer has a low rate of early diagnosis and a poor prognosis. Its incidence rate in the US is estimated at 3.2% of new
          cancer cases. In 2022, approximately 495,000 individuals globally are expected to
            be diagnosed with this condition, 62,000 of them in the US; and the incidence of pancreatic cancer is expected to continue to increase. Symptoms are usually non-specific and as a result, pancreatic cancer is often not diagnosed until it
          reaches an advanced stage. Surgical resection does not offer adequate treatment since only 20% of patients have resectable tumors at the time of diagnosis. Even among patients who undergo resection for pancreatic cancer and have tumor-free
          margins, the five-year survival rate is only 10-25%. The overall five-year survival rate among pancreatic cancer patients is 8%, which constitutes the highest
          mortality rate among solid tumor malignancies. The overall median survival is less than one year from diagnosis, highlighting the need for the development of new therapeutic options.</div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Despite advances in chemotherapeutics and immunotherapy, increases in median and overall survival rates in pancreatic cancer have been modest. Pancreatic cancer remains an area of unmet medical
        need, with very limited new approved therapies for the majority of PDAC patients since the approval of nab-paclitaxel (Abraxane&#174;) in combination with gemcitabine for first-line treatment in 2013 and Onivyde&#174; in combination with fluorouracil and
        leucovorin for second-line treatment in 2015. The limited clinical benefits demonstrated by these existing standard treatment options reinforce the need for additional approaches.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About COMBAT/KEYNOTE-202</div>
      <div style="text-align: justify; line-height: 1.25;">In December 2020, <u>BioLineRx announced final positive results</u> from its Phase 2a COMBAT/KEYNOTE-202 triple combination study of Motixafortide in second line PDAC. The highly encouraging
        results demonstrated improvement across all study endpoints, including overall survival, progression free survival and overall response rate, in the most challenging PDAC patients, as compared to historical data. All patients were diagnosed at
        Stage IV, and greater than 70% had liver metastases, a key determinant of poor prognoses in this patient population.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About GenFleet Therapeutics</div>
      <div style="text-align: justify; line-height: 1.25;">GenFleet Therapeutics is a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, founded in 2017 by veteran drug developers with the support from
        top-tier venture capital investors. Dedicated to serving significant unmet medical needs, GenFleet Therapeutics established its proprietary R&amp;D platform based on a deep understanding of disease biology and translational medicine, as well as on
        research into the latest biological mechanisms of cancer pathways, the tumor microenvironment and human immunoregulation. GenFleet's rich and diversified pipeline highlights multiple cutting-edge products with novel mechanisms and global IP.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">For additional information on GenFleet, please visit the Company's website at www.genfleet.com/en.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About BioLineRx</div>
      <div style="text-align: justify; line-height: 1.25;">BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company's lead program, Motixafortide (BL-8040), is a cancer therapy platform that was
        successfully evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation, has reported positive results from a pre-planned pharmacoeconomic study, has successfully completed a pre-NDA meeting with the FDA, and
        is currently in preparations for an NDA submission. Motixafortide was also successfully evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and chemotherapy and is currently being studied in
        combination with LIBTAYO<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and chemotherapy as a first-line PDAC therapy.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">BioLineRx is also developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">For additional information on BioLineRx, please visit the Company's website at <u>www.biolinerx.com</u>, where you can review the Company's SEC filings, press releases, announcements and events.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation
        Reform Act of 1995. These statements include words such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; and &#8220;would,&#8221; and describe opinions about future
        events. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or
        achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the
        initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx's ability to advance its therapeutic candidates into clinical trials or to successfully
        complete its preclinical studies or clinical trials; BioLineRx's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market
        acceptance of BioLineRx's therapeutic candidates; BioLineRx's ability to establish and maintain corporate collaborations; BioLineRx's ability to integrate new therapeutic candidates and new personnel; the interpretation of the properties and
        characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and
        therapeutic candidates; the scope of protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property
        rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the United
        States or elsewhere; competitive companies, technologies and BioLineRx's industry; statements as to the impact of the political and security situation in Israel on BioLineRx's business; and the impact of the COVID-19 pandemic and the Russian
        invasion of Ukraine, which may exacerbate the magnitude of the factors discussed above. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities
        and Exchange Commission on March 16, 2022. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does
        not assume any obligation to update any forward-looking statements unless required by law.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Contact:</div>
        <div style="text-align: justify; line-height: 1.25;">Tim McCarthy</div>
        <div style="text-align: justify; line-height: 1.25;">LifeSci Advisors, LLC</div>
        <div style="text-align: justify; line-height: 1.25;">+1-212-915-2564</div>
        <div style="text-align: justify; line-height: 1.25;"><u>tim@lifesciadvisors.com</u></div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; line-height: 1.25;">or</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; line-height: 1.25;">Moran Meir</div>
        <div style="text-align: justify; line-height: 1.25;">LifeSci Advisors, LLC</div>
        <div style="text-align: justify; line-height: 1.25;">+972-54-476-4945</div>
      </div>
      <div style="text-align: justify; line-height: 1.25;"><u>moran@lifesciadvisors.com</u></div>
    </div>
    <div> <br>
    </div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !8 HP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *R/%&J3Z)X5U35+9(WGM+9YD60$J2
M!D9P0<?C6O7-_$'_ ))YX@_Z\9?_ $$U4=9(3V/'_P#A>WBC_GPTC_OS+_\
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M_';_ )$>S_[",?\ Z+DKY[KZ$^.W_(CV?_81C_\ 1<E?/=/!_P (,7\9[!\
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MC_%1],4445XAZH4444 %%%% !1110!XO\??]7HO^_)_(5XI7M?Q]_P!7HO\
MOR?R%>*5[&$_A(\S%?Q#W/X _P#((UO_ *^H_P#T"H/C[_J-%_WY/Y5/\ ?^
M01K?_7U'_P"@5!\??]1HO^_)_*N7_F*_KL=/_,/\CQ.O4H?AI_PD7PVTO6='
M0+JB1'S8N@N "?R;^=>6U]0_"O\ Y)QI/_7,_P S71BJDH14H]SGPT%-M,^8
M)8I()7BE1DD1BK(PP5([&I+.\N=/O(KNSGD@N(FW))&<%37T#\2_AG'XBB?5
M](C6/5D&7C' N /_ &;W[U\]2Q202O%*C1R(Q5D88*D=C6E*K&K$BK2E2D?2
MGPZ^(MOXOM!9WA2'6(5^>/H)@/XU_J.WTKO:^,K2[N+"[BN[29X;B%@\<B'!
M4CO7TA\.OB+;^+K06=X4AUB%?GCZ"8#^-?ZCM]*X<3AN3WH['70K\_NRW.]K
MY1^(?_)1=?\ ^OH_^@K7U=7RC\0_^2BZ_P#]?1_]!6G@?C?H&+_AF!9_\?\
M:_\ 7=/_ $(5]ER$K&S#J 37QI9_\?\ :_\ 7=/_ $(5]E3?ZF3_ '358[>)
M.#^%GQSJ;%M7OF/5KF4G_OLUN_#W^S/^$VL?[9^Q_8,/YGVS;Y73C.[BL#4?
M^0I>_P#7Q)_Z$:KUW./-"QQ\W+4N?3W_ !;#_J4/_):C_BV'_4H?^2U?,-%<
MWU3^\S?ZU_=1]/?\6P_ZE#_R6H_XMA_U*'_DM7S#11]4_O,/K7]U'T]_Q;#_
M *E#_P EJ4#X8D@ >$"2< ?Z-7S!3X/^/F'_ *Z+_,4/"?WF-8F[MRH^MO\
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M[:=8T\A"HP5SSDFHJ8:<(\TBX5X3=D<I\??]7HO^_)_(5XI7M?Q]_P!7HO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
